Recently, Cangzhou Sicheng Glass Co., Ltd. made an announcement regarding the successful completion of a Pre-IPO funding round, amassing hundreds of millions of yuan. This round was jointly spearheaded by the CICC Zhongxin Emerging Industry Fund and the Chunguang Qixiang Fund, both entities operating under the umbrella of CICC Capital. The infusion of capital from this funding round is poised to expedite the localization endeavors for high-end, innovative drug delivery devices, including Grade I water-resistant pharmaceutical medium borosilicate glass and prefilled syringes.

Sicheng Glass is dedicated to the autonomous production and marketing of products like neutral borosilicate glass tubes designed for pharmaceutical packaging. The company has achieved a significant milestone by fully developing a domestically produced technology for the entire prefilled syringe supply chain, coupled with the establishment of an integrated, intelligent production and operation system.

As the pioneering domestic enterprise capable of consistently manufacturing medium borosilicate glass tubes that adhere to international standards on a large scale, Sicheng Glass stands out in terms of scale within the medium borosilicate glass bottle production industry. It boasts a client base of over 700 downstream pharmaceutical enterprises.

Driven by the progression of industry policies, the substitution process for medium borosilicate glass is gaining momentum. The prefilled syringe and integrated pharmaceutical CMPO (Contract Manufacturing and Packaging Organization) intelligent manufacturing service sectors are anticipated to emerge as fresh catalysts for the company's performance growth.

Chairman Wang Huanyi expressed that the company will persist in prioritizing innovation, intelligent manufacturing, and green energy initiatives to steer the industry toward a trajectory of high-quality and sustainable development.